Ranolazine Patent Expiration
Ranolazine was first introduced by Menarini International Operations Luxembourg Sa
Ranolazine Patents
Given below is the list of patents protecting Ranolazine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aspruzyo Sprinkle | US10898444 | Extended release multiparticulates of ranolazine | Jan 24, 2038 | Spil |
| Aspruzyo Sprinkle | US11510878 | Extended release multiparticulates of ranolazine | Jan 24, 2038 | Spil |
| Aspruzyo Sprinkle | US12161761 | Extended release multiparticulates of ranolazine | Jan 24, 2038 | Spil |
| Ranexa | US6303607 | Method for administering a sustained release ranolanolazine formulation |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6369062 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6479496 | Methods for treating angina with ranolazine |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6503911 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6525057 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6562826 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6617328 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6620814 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6852724 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
| Ranexa | US6864258 | Sustained release ranolazine formulations |
May 27, 2019
(Expired) | Menarini Intl |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ranolazine's patents.
Latest Legal Activities on Ranolazine's Patents
Given below is the list recent legal activities going on the following patents of Ranolazine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 20 Dec, 2016 | US6620814(Litigated) |
| File Marked Found | 15 Dec, 2016 | US6525057(Litigated) |
| File Marked Found | 12 Dec, 2016 | US6525057(Litigated) |
| Post Issue Communication - Certificate of Correction | 11 Aug, 2015 | US6562826(Litigated) |
| Case Docketed to Examiner in GAU Critical
| 05 Aug, 2015 | US6562826(Litigated) |
| Post Issue Communication - Certificate of Correction | 19 Mar, 2015 | US6620814(Litigated) |
| Post Issue Communication - Certificate of Correction | 21 Jan, 2015 | US6852724(Litigated) |
| Correspondence Address Change Critical
| 01 Mar, 2012 | US6525057(Litigated) |
| Correspondence Address Change Critical
| 01 Mar, 2012 | US6562826(Litigated) |
| Correspondence Address Change Critical
| 01 Mar, 2012 | US6503911(Litigated) |
Ranolazine's Family Patents
